The pUT-Tn5-EM7-lux-Km1 luminescent construct vector was a gracious gift from J. Hardy. Schematics were created with BioRender.com. We thank the lab of G. Gurtner for their advice on the wound infection model. We also thank T. Doyle from the Stanford Center for Innovation in In Vivo Imaging for his technical expertise. This work was supported by grants R21AI133370, R21AI133240, R01AI12492093, and grants from Stanford SPARK, the Falk Medical Research Trust and the Cystic Fibrosis Foundation (CFF) to P.L.B. C.R.D was supported by T32AI007502. A Gabilan Stanford Graduate Fellowship for Science and Engineering and a Lubert Stryer Bio-X Stanford Interdisciplinary Graduate Fellowship supported J.M.S.

All methods described here have been approved by the Institutional Animal Care and Use Committee (IACUC) at Stanford University.
1. Preparation and growth of bacteria
<ol>
	<li>Conduct all work with P. aeruginosa and animals with BSL-2 precautions per the researcher&#39;s institutional biosafety committee and animal use committee guidelines. Do all steps described here involving P. aeruginosa, including mouse inoculation, in a biosafety cabinet.</li>
	<li>The luminescent PAO1:lux strain of P. aeruginosa is available from our lab by request. Streak PAO1, stored as frozen glycerol stock, on Lysogeny Broth (LB) agar. For the luminescent PAO1:lux strain, LB agar should contain selective antibiotics (100 &#181;g/mL carbenicillin and 12.5 &#181;g/mL kanamycin). Grow at 37 &#176;C overnight in a bacterial incubator.</li>
	<li>Pick an isolated colony and grow overnight at 37 &#176;C in 3 ml LB medium, pH 7.4. For luminescent strains, broth should contain 100 &#181;g/mL carbenicillin. Grow under shaking, aerobic conditions.</li>
</ol>
2. Procedure preparation
<ol>
	<li>Have all personnel performing surgery wear a clean gown/Lab coat, face mask, hair net, and gloves.</li>
	<li>Autoclave all surgical tools, including scissors and forceps. Use aseptic technique to sterilize tools between animals.</li>
	<li>Clean the surgical table with ethanol and prepare a clean surgical field.</li>
</ol>
3. Hair removal
<ol>
	<li>Anesthetize 8&#8211;12 week old C57BL/6J mice using 1%&#8211;3% isoflurane. Investigators should follow their institution&#39;s veterinary staff guidelines for anesthesia when using isoflurane.
	<ol>
		<li>Start anesthesia by delivering 1%&#8211;3% isoflurane and adjust oxygen flow rate to 1.5 L/min. Place the mouse in the induction chamber.</li>
		<li>Pinch the mouse&#39;s toe to assess depth of anesthesia. When the mouse no longer responds to stimulation, remove it from the induction chamber and place it on the surgical bench with its nose in the isoflurane nose cone.</li>
		<li>Apply ocular lubricant to both eyes.</li>
	</ol>
	</li>
	<li>Weigh the mouse to obtain a baseline pre-procedure weight.</li>
	<li>Place the mouse in prone position. Inject the mouse subcutaneously with pre-warmed sterile 0.9% sodium chloride, 250 &#181;L at each flank for a total of 500 &#181;L.</li>
	<li>Shave the dorsal area of the mouse using an electric shaver. Shaving should occur at a different location than the surgical station to prevent hair contamination of the wound.</li>
	<li>Apply a thin layer of hair removal lotion. Let the lotion sit for 20&#8211;60 s. Remove the hair and excess lotion with gauze moistened in warm water. Following hair removal, proceed to the excisional wounding procedure.</li>
</ol>
4. Full thickness excisional wound surgery
<ol>
	<li>Inject sustained release buprenorphine 0.6&#8211;1 mg/kg subcutaneously using a 25 G needle at the mid-dorsal area of the mouse. Slow release buprenorphine provides pain relief over 48&#8211;72 h.</li>
	<li>Disinfect the surgical site. Wipe the dorsal surface with a sterile betadine swab. Wipe excess betadine with a sterile alcohol swab. This should be performed 3 times (alternating between betadine and alcohol), swabbing by moving from the center in a circular manner to the edge. Allow the area to air dry.</li>
	<li>Create a drape surrounding the surgical site using sterile gauze or plastic cling wrap.</li>
	<li>Stretch skin taut caudally. Use a sterile 6-mm diameter skin biopsy punch to make an initial incision through the left dorsal epidermis. Repeat on the right dorsal epidermis.</li>
	<li>Use forceps to tent the skin from the center of the left outlined wound area. Excise the epidermal and dermal layers using scissors. Repeat on the right outlined wound area to create symmetrical excisional wounds.</li>
	<li>Wash wounds with 50 &#181;L of sterile saline. Allow the surgical site and surrounding skin to air dry. Then, cover the wounds and dorsum with a transparent film dressing.</li>
	<li>Place the mouse back in a clean cage. House 1 animal per cage.</li>
	<li>Place the cage on a heating pad and monitor until the mouse wakes up.</li>
	<li>When performing the above surgery on multiple animals, use a hot bead sterilizer to clean all surgical instruments between animals.</li>
	<li>Allow 24 h for the mice to recover from the surgical procedure and for formation of a provisional wound matrix over the wounds prior to proceeding to inoculation with bacteria.</li>
</ol>
5. Inoculation with P. aeruginosa
<ol>
	<li>Dilute overnight PAO1:lux culture to OD600 = 0.05 in 75 mL of LB media containing 100 &#181;g/mL carbenicillin and grow the bacteria until the culture is in early exponential phase (OD600 &#8776; 0.3). This should take approximately 2&#8211;3 h.</li>
	<li>Dilute PAO1:lux in PBS to a concentration of (7.5 &#177; 2.5) x 102 CFU/mL. Be sure to prepare excess inoculum to ensure sufficient volume and to allow for plating after the experiment. If transporting between facilities (i.e. from the lab to the vivarium), use double containment in a leak proof box clearly marked Biohazard.</li>
	<li>Perform all work with P. aeruginosa and mice using approved personal protective equipment in an Animal Biosafety Level 2 (ABSL-2) approved biological safety cabinet (BSC). Reusable equipment such as the weighing scale should be covered with cling wrap to prevent contamination.</li>
	<li>Anesthetize using 3% isoflurane as described above. Weigh mouse and record the weight. Inject the mouse subcutaneously with pre-warmed sterile 0.9% sodium chloride, 250 &#181;L at each flank for a total of 500 &#181;L.</li>
	<li>If the mouse&#39;s transparent film dressing has come off overnight, remove any resulting scab carefully and put on a new dressing.</li>
	<li>Use a 500 &#181;L tuberculin 27 G safety cap syringe to inject 40 &#181;L of the PAO1:lux suspension through the transparent film dressing into each wound. Different mice should be used for non-inoculated/PBS wound controls in order to prevent cross-contamination from the contralateral side.</li>
	<li>Place the mouse back in its cage on a heating pad and monitor until it wakes up. All mice should be housed individually in separate cages to prevent cross-contamination.</li>
	<li>Provide high calorie nutritional supplement paste sandwiched between food pellets on the floor of the cage.</li>
	<li>Use the remaining inoculum to streak an LB agar plate. Count colonies to confirm the number of bacteria administered.</li>
</ol>
6. In vivo imaging of infected wounds
<ol>
	<li>Follow BSL-2 containment protocols for transport of mice to and from the imaging instrument, including use of a secondary container. Be careful not to transfer or drop any animal bedding during the transfer of the mouse to the induction chamber or imaging instrument.</li>
	<li>Induce anesthesia of the mouse with inhaled 1%&#8211;3% isoflurane in an induction chamber as described in step 3.1.</li>
	<li>Once the mouse is anesthetized, place it in prone position in the imaging chamber of an optical imaging system with the nose in the isoflurane nose cone.</li>
	<li>Open the software program.</li>
	<li>The acquisition parameters will vary based on the number of animals imaged simultaneously and intensity of bioluminescence. The basic parameters to set include exposure time, binning, f/stop, and field of view (FOV). Our default starting settings are exposure time 30 seconds, binning low (2), f/stop 1.2, and FOV 25. Adjust these settings as needed depending on the researcher&#39;s needs.</li>
	<li>Analyze luminescence data using an imaging program (see Table of Materials). Luminescence will be represented as a pseudocolor image overlaid on a color photograph of the mice.
	<ol>
		<li>Create a region of interest (ROI) at the wound site and measure the average flux (photons/second) detected. Note that data can also be reported as radiance (photons/second/cm&#178;/steradian), but as long as the distance of the imaging platform from the camera remains constant between imaging, flux is sufficient.</li>
		<li>Measure background by creating a ROI at a random area on the imaging platform. Subtract the background number of photons/second.</li>
		<li>Export the data to a spreadsheet for further analysis.</li>
	</ol>
	</li>
	<li>Perform imaging as described above as often as daily to track infection progression.</li>
</ol>
7. Postoperative management
<ol>
	<li>Monitor mice according to guidelines set by the researcher&#39;s IACUC protocol. We monitor all mice daily for the first 4 days, then every other day until the end of the experiment. Weigh the mice once per day for the first 4 days post-surgery in a BSC. Inject 250 &#181;L of 0.9% sodium chloride subcutaneously on post-infection days 1 and 2.</li>
	<li>Check for signs of pain/distress in the mice, including hunched posture, scruffy coat, lethargy, difficulty breathing, facial grimace, and weight loss.</li>
	<li>If animals display signs of deteriorating health, consult with a veterinarian. Any mouse that appears to show worsening signs of pain/distress and a weight loss of 20% or greater should be euthanized.</li>
</ol>
8. Wound excision
<ol>
	<li>At the end of the experiment, sacrifice the mice using CO2 inhalation, followed by cervical dislocation. Dispose of the animal carcass according to the institution&#39;s ABSL-2 protocols.</li>
	<li>Excise wound beds using sterile scissors and forceps in a BSC. Place each wound bed in 1 mL sterile PBS in a 1.5 mL polypropylene tube. Mince the wound tissue with scissors. All wounds should be treated as ASBL-2, even if they are not considered infected.</li>
	<li>Incubate on a shaker at 300 rpm for 2 h at 4 &#176;C. Vortex each tube for 10 s and serially dilute the bacterial effluent in PBS. Plate the diluted bacterial effluent on LB agar to enumerate the bacterial burden.</li>
	<li>Consider wounds infected if luminescent signal in the wound is above background luminescence and more bacteria are detected in the wound effluent than in wounds inoculated with PBS as control.</li>
</ol>

<ol><li>Sen, C. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+skin+wounds%3A+a+major+and+snowballing+threat+to+public+health+and+the+economy%5BTitle%5D)+AND+%22Wound+Repair+and+Regeneration%22%5BJournal%5D)">Human skin wounds: a major and snowballing threat to public health and the economy.</a> Wound Repair and Regeneration. 17 (6), 763-771 (2009).</li>
<li>Serra, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chronic+wound+infections%3A+the+role+of+Pseudomonas+aeruginosa+and+Staphylococcus+aureus%5BTitle%5D)+AND+%22Expert+Review+of+Anti-infective+Therapy%22%5BJournal%5D)">Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus.</a> Expert Review of Anti-infective Therapy. 13 (5), 605-613 (2015).</li>
<li>Obritsch, M. D., Fish, D. N., MacLaren, R., Jung, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nosocomial+infections+due+to+multidrug-resistant+Pseudomonas+aeruginosa%3A+epidemiology+and+treatment+options%5BTitle%5D)+AND+%22Pharmacotherapy%22%5BJournal%5D)">Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.</a> Pharmacotherapy. 25 (10), 1353-1364 (2005).</li>
<li>Secor, P. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Filamentous+Bacteriophage+Produced+by+Pseudomonas+aeruginosa+Alters+the+Inflammatory+Response+and+Promotes+Noninvasive+Infection+In+Vivo%5BTitle%5D)+AND+%22Infection+and+Immunity%22%5BJournal%5D)">Filamentous Bacteriophage Produced by Pseudomonas aeruginosa Alters the Inflammatory Response and Promotes Noninvasive Infection In Vivo.</a> Infection and Immunity. 85 (1), (2017).</li>
<li>Rice, S. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+biofilm+life+cycle+and+virulence+of+Pseudomonas+aeruginosa+are+dependent+on+a+filamentous+prophage%5BTitle%5D)+AND+%22The+ISME+Journal%22%5BJournal%5D)">The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage.</a> The ISME Journal. 3 (3), 271-282 (2009).</li>
<li>Bayes, H. K., Ritchie, N., Irvine, S., Evans, T. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+murine+model+of+early+Pseudomonas+aeruginosa+lung+disease+with+transition+to+chronic+infection%5BTitle%5D)+AND+%22Scientific+Reports%22%5BJournal%5D)">A murine model of early Pseudomonas aeruginosa lung disease with transition to chronic infection.</a> Scientific Reports. 6, 35838(2016).</li>
<li>van Gennip, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Interactions+between+polymorphonuclear+leukocytes+and+Pseudomonas+aeruginosa+biofilms+on+silicone+implants+in+vivo%5BTitle%5D)+AND+%22Infection+and+Immunity%22%5BJournal%5D)">Interactions between polymorphonuclear leukocytes and Pseudomonas aeruginosa biofilms on silicone implants in vivo.</a> Infection and Immunity. 80 (8), 2601-2607 (2012).</li>
<li>Trøstrup, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pseudomonas+aeruginosa+biofilm+aggravates+skin+inflammatory+response+in+BALB%2Fc+mice+in+a+novel+chronic+wound+model%5BTitle%5D)+AND+%22Wound+Repair+and+Regeneration%22%5BJournal%5D)">Pseudomonas aeruginosa biofilm aggravates skin inflammatory response in BALB/c mice in a novel chronic wound model.</a> Wound Repair and Regeneration. 21 (2), 292-299 (2013).</li>
<li>Zhao, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Time+course+study+of+delayed+wound+healing+in+a+biofilm-challenged+diabetic+mouse+model%5BTitle%5D)+AND+%22Wound+Repair+and+Regeneration%22%5BJournal%5D)">Time course study of delayed wound healing in a biofilm-challenged diabetic mouse model.</a> Wound Repair and Regeneration. 20 (3), 342-352 (2012).</li>
<li>Brubaker, A. L., Rendon, J. L., Ramirez, L., Choudhry, M. A., Kovacs, E. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Reduced+neutrophil+chemotaxis+and+infiltration+contributes+to+delayed+resolution+of+cutaneous+wound+infection+with+advanced+age%5BTitle%5D)+AND+%22Journal+of+Immunolology%22%5BJournal%5D)">Reduced neutrophil chemotaxis and infiltration contributes to delayed resolution of cutaneous wound infection with advanced age.</a> Journal of Immunolology. 190 (4), 1746-1757 (2013).</li>
<li>Watters, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pseudomonas+aeruginosa+biofilms+perturb+wound+resolution+and+antibiotic+tolerance+in+diabetic+mice%5BTitle%5D)+AND+%22Medical+Microbiology+and+Immunology%22%5BJournal%5D)">Pseudomonas aeruginosa biofilms perturb wound resolution and antibiotic tolerance in diabetic mice.</a> Medical Microbiology and Immunology. 202 (2), 131-141 (2013).</li>
<li>Lee, C., Kerrigan, C. L., Picard-Ami, L. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cyclophosphamide-induced+neutropenia%3A+effect+on+postischemic+skin-flap+survival%5BTitle%5D)+AND+%22Plastic+and+Reconstructive+Surgery%22%5BJournal%5D)">Cyclophosphamide-induced neutropenia: effect on postischemic skin-flap survival.</a> Plastic and Reconstructive Surgery. 89 (6), 1092-1097 (1992).</li>
<li>Sweere, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+immune+response+to+Chronic+Pseudomonas+aeruginosa+wound+infection+in+immunocompetent+mice%5BTitle%5D)+AND+%22Advances+in+Wound+Care%22%5BJournal%5D)">The immune response to Chronic Pseudomonas aeruginosa wound infection in immunocompetent mice.</a> Advances in Wound Care. , (2019).</li>
<li>Sweere, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Bacteriophage+trigger+antiviral+immunity+and+prevent+clearance+of+bacterial+infection%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection.</a> Science. 363 (6434), (2019).</li>
</ol>

The authors have no competing financial interests to disclose.

We have developed a novel delayed inoculation P. aeruginosa wound infection model. The strategy of delaying inoculation with bacteria until 24 h after excisional wounding enables the evaluation of wound infections over a 1-week timeframe. By using a luminescent strain of P. aeruginosa, it is possible to track infection progression throughout the infection course. The longer course of infection compared to other P. aeruginosa infection models will allow new opportunities for studying host-pathogen interactions and novel therapies targeting P. aeruginosa wound infections. For example, we have already used this model to demonstrate the role of Pf bacteriophage in stimulating an antiviral immune response that allows P. aeruginosa to evade the host immune system14.
The inclusion of 24 h of recovery time between the excisional wound surgery and bacterial inoculation is a critical step in this wound infection model. It allows the animals to recover from the wound surgery before being infected, which likely plays a role in their ability to survive through at least 7 days. Furthermore, it supports the formation of a provisional wound matrix prior to inoculation, which, in combination with the transparent film dressing, provides an environment conducive to biofilm formation. We performed a series of exploratory experiments during the development of this model looking at different amounts of time between wounding and inoculation. In our experience, immediate inoculation after wounding often results in sepsis and death. Conversely, inoculation at 48 hours and later time points led to unacceptable levels of heterogeneity between mice and between wounds on the same mouse. As evident in Figure 3A, there can still be some degree of expected heterogeneity in the bacterial load of infected wounds, even with the 24-h delayed inoculation. One way to compensate for this is to use multiple animals in each experiment.
A unique aspect of this protocol is the excision of two wounds independently rather than folding the skin down the midline and punching through to create two bilateral wounds, as is done in some other wound models. We found that this folding method was also effective for producing symmetrical wounds with clean margins. However, mice treated in this manner typically became septic quickly after bacterial inoculation and died. We believe that this may be because this folding method removes the dermal Panniculus carnosus - a thin layer of muscle underlying the skin of mice that is not present in humans. We speculate that this barrier may help prevent bacterial dissemination.
An important component of this protocol is sufficient hair removal from the surgical site, as excess hair could provide a nidus for superinfection and interferes with adherence of the transparent film dressing. We have found that shaving in addition to hair removal cream provides optimal hair removal with minimal skin irritation, though thoroughly washing off the cream with warm water is still important.
Another integral factor is nutritional support, hydration, and pain control during the first few days of the postsurgical and infection course. To address this, we administer 500 &#181;L of subcutaneous 0.9% sodium chloride on day -1 and 0, then 250 &#181;L on day 1 and 2. We also supply a multivitamin and caloric liquid gel supplement at the time of the excisional wound surgery. As demonstrated in Figure 3E, these measures allow for adequate recovery of weight by Day 3. With regard to analgesia, we have found that sustained release 0.5 mg/kg buprenorphine given prior to the excisional wound surgery provides sufficient pain control for 72 h, but additional doses can be given if warranted based on findings of distress in any individual mouse.
Though a model of P. aeruginosa wound infection extending to 7&#8211;10 days is a significant advantage over more acute models of infection, this still may not be sufficient for answering certain research questions involving more chronic infections. One reason for this limitation is that the luminescent signal of the PAO1:lux strain of P. aeruginosa peaks at day 2&#8211;3 (Figure 3B). After ~7 days the luciferase signal can become unreliable. For this reason, we quantify the bacteria by plating wound effluent on LB plates and counting CFUs in order to confirm infection of each wound at the end of the experiment. Another possible disadvantage of this model is the requirement for an in vivo imaging system, which some labs may not have access to. One way around this obstacle is to use non-luminescent wild type bacterial strains. This still allows the researcher to take advantage of this chronic infection model and, as indicated above, the bacteria CFUs can be quantified at the end of the experiment.
We have described a novel model of delayed inoculation P. aeruginosa wound infection that enables experiments extending to 7&#8211;10 days. This model will serve as a useful tool for evaluating the host-pathogen interaction with P. aeruginosa, as well as the development of new therapies. This model has the potential for multiple future directions, including adaptation for other wound pathogens such as Staphylococcus aureus, as well as polymicrobial infections including P. aeruginosa combined with other pathogens.

Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative rod-shaped bacterium with increasing relevance to human health and disease. It is responsible for extensive morbidity and mortality in nosocomial settings, particularly involving wound infections in immunocompromised patients1,2. The emergence of multidrug-resistant strains of this pathogen has provided further impetus for investigation into factors contributing to P. aeruginosa virulence, mechanisms of P. aeruginosa antibiotic resistance, and new methods for prevention and treatment of this deadly infection3. As such, the need for animal models of chronic wound infection as tools for investigating these research questions has never been greater.
Unfortunately, many animal models of P. aeruginosa infection tend to simulate acute infection with rapid resolution of infection or rapid decline due to sepsis4,5, which does not adequately simulate the oftentimes chronic nature of these infections. To address this drawback, some models utilize the implantation of foreign bodies such as agar beads, silicone implants, or alginate gels6,7,8. Other models use mice that are immunocompromised due to advanced age, obesity, or diabetes, or through pharmacological means such as cyclophosphamide-induced neutropenia9,10,11,12. However, either the use of foreign materials or immune compromised hosts likely alters the local inflammatory process, making it difficult to gain an understanding of the pathophysiology involved in chronic wound infections in hosts with otherwise normal immune systems.
We have developed a chronic model of P. aeruginosa wound infection in mice that involves delayed inoculation with bacteria after excisional wounding. Delayed inoculation allows for experiments assessing bacterial burden extending out to at least 7 days. This model opens up new opportunities for investigating both pathogenesis and new treatments of P. aeruginosa chronic infections.

<table><tbody><tr><td>0.9% Sodium Chloride injection</td><td>Hospira</td><td>2484457</td><td></td></tr><tr><td>18 G x 1 sterile needle</td><td>BD</td><td>305195</td><td></td></tr><tr><td>25 G x 1 1/5 sterile needle</td><td>BD</td><td>305127</td><td></td></tr><tr><td>Alcohol swab</td><td>BD</td><td>326895</td><td></td></tr><tr><td>Aura Imaging Software</td><td>Spectral Instruments Imaging</td><td>n/a</td><td></td></tr><tr><td>Betadine</td><td>Purdue Frederick Company</td><td>19-065534</td><td></td></tr><tr><td>Buprenorphine SR LAB</td><td>Zoopharm</td><td>n/a</td><td></td></tr><tr><td>C57BL/6J male mice</td><td>The Jackson Laboratory</td><td>000664</td><td></td></tr><tr><td>Disposable biopsy punch, 6mm</td><td>Integra</td><td>33-36</td><td></td></tr><tr><td>Fine scissors - Tungsten Carbide</td><td>Fine Science Tools</td><td>14568-09</td><td></td></tr><tr><td>Glass Bead Dry Sterilizer</td><td>Harvard Apparatus</td><td>61-0183</td><td></td></tr><tr><td>Granulated Agar</td><td>Fisher BioReagents</td><td>BP9744</td><td></td></tr><tr><td>Heating Pad</td><td>Milliard</td><td>804879481218</td><td></td></tr><tr><td>Insulin syringe with 28 G needle</td><td>BD</td><td>329461</td><td></td></tr><tr><td>Lago X Imaging System</td><td>Spectral Instruments Imaging</td><td>n/a</td><td></td></tr><tr><td>LB broth</td><td>Fisher BioReagents</td><td>BP1426</td><td></td></tr><tr><td>Leur-Lok 1 mL syringe</td><td>BD</td><td>309628</td><td></td></tr><tr><td>Mini Arco Animal Trimmer</td><td>Wahl Professional</td><td>919152</td><td></td></tr><tr><td>Nair Hair Removal Lotion with Baby Oil</td><td>Church and Dwight</td><td>n/a</td><td>Available at any pharmacy</td></tr><tr><td>Octagon Forceps</td><td>Fine Science Tools</td><td>11041-08</td><td></td></tr><tr><td>Petri dish</td><td>Falcon</td><td>351029</td><td></td></tr><tr><td>Phosphate Buffered Saline (PBS) 1x</td><td>Corning</td><td>21-040-CV</td><td></td></tr><tr><td>Press and Seal Cling Wrap</td><td>Glad</td><td>n/a</td><td></td></tr><tr><td>SafetyGlide Insulin syringe with 30 G needle</td><td>BD</td><td>305934</td><td></td></tr><tr><td>Safetyglide Insulin syringe, 1/2 mL, 30 G x 5/16 TW</td><td>BD</td><td>305934</td><td></td></tr><tr><td>Scale</td><td>Ohaus Scout Pro</td><td>SP202</td><td></td></tr><tr><td>Supplical Nutritional Supplement</td><td>Henry Schein Animal Health</td><td>29908</td><td></td></tr><tr><td>Tegaderm, 6 cm x 7 cm</td><td>3M</td><td>1624W</td><td></td></tr></tbody></table>

a delayed inoculation model of chronic pseudomonas aeruginosa wound infection

Pseudomonas aeruginosa (P. aeruginosa) is a major nosocomial pathogen of increasing relevance to human health and disease, particularly in the setting of chronic wound infections in diabetic and hospitalized patients. There is an urgent need for chronic infection models to aid in the investigation of wound pathogenesis and the development of new therapies against this pathogen. Here, we describe a protocol that uses delayed inoculation 24 hours after full-thickness excisional wounding. The infection of the provisional wound matrix present at this time forestalls either rapid clearance or dissemination of infection and instead establishes chronic infection lasting 7&#8211;10 days without the need for implantation of foreign materials or immune suppression. This protocol mimics a typical temporal course of post-operative infection in humans. The use of a luminescent P. aeruginosa strain (PAO1:lux) allows for quantitative daily assessment of bacterial burden for P. aeruginosa wound infections. This novel model may be a useful tool in the investigation of bacterial pathogenesis and the development of new therapies for chronic P. aeruginosa wound infections.

Using a luminescent strain of PAO1 with a plasmid encoding the luxABCDE reporter system (PAO1:lux), we performed excisional wounding on mice, inoculated these wounds with planktonic P. aeruginosa 24 h later, and measured bacterial burden over time (Figure 1 and Figure 2). A representative image obtained using an imaging optical system demonstrates that this model results in detectable luminescence (Figure 3A). Infection peaked at day 3 post-inoculation and persisted 7 days post-inoculation based on both bioluminescence and colony counts (Figure 3B&#8211;C). Using this model, we are able to reliably generate wounds lasting 7-10 ays depending on the strain of bacteria and the mouse background. Culture of the bacteria isolated from the wound showed that quantified CFU/wound correlated with detected luminescence (Figure 3D). Finally, despite demonstrable and quantifiable P. aeruginosa infection, mice survived for at least 7 days. Though there was initial rapid weight loss immediately after infection, saline injections and supplemental nutrition resulted in restoration of weight (Figure 3E). Finally, we calculated the inoculation dose at which 50% of wounds would become sustainably infected with PAO1. The calculated IC50 value was ~7.7 x 102 CFU/mL. Doses higher than 104 CFU/mL resulted in 100% infection rate (Figure 3F). These results were adapted from previously published data13.
<img alt="Figure 1" class="xfigimg" src="/files/ftp_upload/60599/60599fig01.jpg" /> 
Figure 1: Schematic depicting the excisional full-thickness wound infection model with delayed inoculation with bioluminescent P. aeruginosa. Streak PAO1:lux on day -2. Select a colony on day -1 and grow overnight in LB broth. Perform excisional wound surgery on day -1. On day 0, inoculate with PAO1:lux by injecting into the wound bed through the transparent film dressing. Perform bioluminescence imaging after inoculation. Repeat imaging as often as daily through day 7&#8211;10. On day 7&#8211;10, sacrifice animals and harvest wounds. <a href="https://www.jove.com/files/ftp_upload/60599/60599fig01large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 2" class="xfigimg" src="/files/ftp_upload/60599/60599fig02.jpg" /> 
Figure 2: Schematic of excisional wound surgery. After hair removal and sterilization of skin with alcohol and betadine, use a 6 mm biopsy punch to make an initial incision through the epidermis of the left and right dorsum. Use scissors and forceps to remove the dermal and epidermal layers. Wash with PBS. Cover with a clear dressing. <a href="https://www.jove.com/files/ftp_upload/60599/60599fig02large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 3" class="xfigimg" src="/files/ftp_upload/60599/60599fig03.jpg" /> 
Figure 3: P. aeruginosa wound infection can be detected through 7 days of infection. (A) Representative image of a mouse infected with PAO1:lux with bioluminescence overlay on excisional wounds. (B) Luminescent signal reflecting wound bacterial burden. N = 6 wounds. Inoculation: 105 CFU/mL PAO1. (C) Linear regression analysis of in vivo luminescent signal and bacterial CFU of PAO1:lux-infected wounds, collected 4&#8211;7 days post-inoculation with 105 CFU/mL to allow for a range of bacterial burdens. (D) Bacterial burden in CFU/wound over time in mice infected with 105 CFU/mL PAO1:lux. (E) Weight change (relative to weight before wound excision surgery on T = -1) N = 4 mice/group. Depicted are boxplots for 5&#8211;95 percentile. Statistics are Two-way ANOVA corrected with Sidak multiple comparison. (F) Nonlinear regression analysis of wound infection rate used to calculate the IC50 for PAO1 three days post-inoculation. All graphs are representative of n&#8805;3 experiments. This figure has been modified from Sweere et al. 201913. <a href="https://www.jove.com/files/ftp_upload/60599/60599fig3alarge.jpg" target="_blank">Please click here to view a larger version of this figure.</a>

Watch this Scientific Journal Video about A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection at JoVE.com

A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection

We describe a delayed inoculation protocol for generating chronic wound infections in immunocompetent mice.

A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection

Pseudomonas aeruginosa (P. aeruginosa) is a major nosocomial pathogen of increasing relevance to human health and disease, particularly in the setting of ...

a-delayed-inoculation-model-chronic-pseudomonas-aeruginosa-wound

Universidad Científica del Sur

Research

JoVE Journal

Immunology and Infection

8.4K Views.  Stanford University. We describe a delayed inoculation protocol for generating chronic wound infections in immunocompetent mice.

Video: A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection

Co-culture Models of Pseudomonas aeruginosa Biofilms Grown on Live Human Airway Cells

Bacterial biofilms have been associated with a number of different human diseases, but biofilm development has generally been studied on non-living surfaces. In this paper, we describe protocols for forming Pseudomonas aeruginosa biofilms on human airway epithelial cells (CFBE cells) grown in culture. In the first method (termed the Static Co-culture Biofilm Model), P. aeruginosa is incubated with CFBE cells grown as confluent monolayers on standard tissue culture plates. Although the bacterium is quite toxic to epithelial cells, the addition of arginine delays the destruction of the monolayer long enough for biofilms to form on the CFBE cells. The second method (termed the Flow Cell Co-culture Biofilm Model), involves adaptation of a biofilm flow cell apparatus, which is often used in biofilm research, to accommodate a glass coverslip supporting a confluent monolayer of CFBE cells. This monolayer is inoculated with P. aeruginosa and a peristaltic pump then flows fresh medium across the cells. In both systems, bacterial biofilms form within 6-8 hours after inoculation. Visualization of the biofilm is enhanced by the use of P. aeruginosa strains constitutively expressing green fluorescent protein (GFP). The Static and Flow Cell Co-culture Biofilm assays are model systems for early P. aeruginosa infection of the Cystic Fibrosis (CF) lung, and these techniques allow different aspects of P. aeruginosa biofilm formation and virulence to be studied, including biofilm cytotoxicity, measurement of biofilm CFU, and staining and visualizing the biofilm.

Co-culture Models of Pseudomonas aeruginosa Biofilms Grown on Live Human Airway Cells

This paper describes different methods of growing Pseudomonas aeruginosa biofilms on cultured human airway epithelial cells. These protocols can be adapted to study different aspects of biofilm formation, including visualization of the biofilm, staining of the biofilm, measuring the colony forming units (CFU) of the biofilm, and studying biofilm cytotoxicity.

Bacterial biofilms have been associated with a number of different human diseases, but biofilm development has generally been studied on non-living ...

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

A mouse model of chronic airway infection is a key asset in cystic fibrosis (CF) research, although there are a number of concerns regarding the model itself. Early phases of inflammation and infection have been widely studied by using the Pseudomonas aeruginosa agar-beads mouse model, while only few reports have focused on the long-term chronic infection in vivo. The main challenge for long term chronic infection remains the low bacterial burden by P. aeruginosa and the low percentage of infected mice weeks after challenge, indicating that bacterial cells are progressively cleared by the host.
This paper presents a method for obtaining efficient long-term chronic infection in mice. This method is based on the embedding of the P. aeruginosa clinical strains in the agar-beads in vitro, followed by intratracheal instillation in C57Bl/6NCrl mice. Bilateral lung infection is associated with several measurable read-outs including weight loss, mortality, chronic infection, and inflammatory response. The P. aeruginosa RP73 clinical strain was preferred over the PAO1 reference laboratory strain since it resulted in a comparatively lower mortality, more severe lesions, and higher chronic infection. P. aeruginosa colonization may persist in the lung for over three months. Murine lung pathology resembles that of CF patients with advanced chronic pulmonary disease.
This murine model most closely mimics the course of the human disease and can be used both for studies on the pathogenesis and for the evaluation of novel therapies.

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

We describe the agar-beads method to establish persistent long-term chronic Pseudomonas aeruginosa airway infection in the mouse model.

A mouse model of chronic airway infection is a key asset in cystic fibrosis (CF) research, although there are a number of concerns regarding the model ...

Pseudomonas aeruginosa Induced Lung Injury Model

In order to study human acute lung injury and pneumonia, it is important to develop animal models to mimic various pathological features of this disease. Here we have developed a mouse lung injury model by intra-tracheal injection of bacteria Pseudomonas aeruginosa (P. aeruginosa or PA). Using this model, we were able to show lung inflammation at the early phase of injury. In addition, alveolar epithelial barrier leakiness was observed by analyzing bronchoalveolar lavage (BAL); and alveolar cell death was observed by Tunel assay using tissue prepared from injured lungs. At a later phase following injury, we observed cell proliferation required for the repair process. The injury was resolved 7 days from the initiation of P. aeruginosa injection. This model mimics the sequential course of lung inflammation, injury and repair during pneumonia. This clinically relevant animal model is suitable for studying pathology, mechanism of repair, following acute lung injury, and also can be used to test potential therapeutic agents for this disease.

Pseudomonas aeruginosa Induced Lung Injury Model

We have developed a mouse lung injury model by intra-tracheal injection of bacteria Pseudomonas aeruginosa. This model mimics lung injury during pneumonia and is clinically relevant.

In order to study human acute lung injury and pneumonia, it is important to develop animal models to mimic various pathological features of this disease. ...

Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways

Studying host-pathogen interaction enables us to understand the underlying mechanisms of the pathogenicity during microbial infection. The prognosis of the host depends on the involvement of an adapted immune response against the pathogen1. Immune response is complex and results from interaction of the pathogens and several immune or non-immune cellular types2. In vitro studies cannot characterise these interactions and focus on cell-pathogen interactions. Moreover, in the airway3, particularly in patients with suppurative chronic lung disease or in mechanically ventilated patients, polymicrobial communities are present and complicate host-pathogen interaction. Pseudomonas aeruginosa and Candida albicans are both problem pathogens4, frequently isolated from tracheobronchial samples, and associated to severe infections, especially in intensive care unit5. Microbial interactions have been reported between these pathogens in vitro but the clinical impact of these interactions remains unclear6. To study the interactions between C. albicans and P. aeruginosa, a murine model of C. albicans airways colonization, followed by a P. aeruginosa-mediated acute lung infection was performed.

Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways

While in vitro study of host-pathogen interactions allow the characterization of specific immune responses, in vivo models are required to observe the effects of complex responses. Using Candida albicans exposure followed by Pseudomonas aeruginosa-mediated lung infection, we established a murine model of microbial interactions involved in ventilator-associated pneumonia pathogenicity.

Studying host-pathogen interaction enables us to understand the underlying mechanisms of the pathogenicity during microbial infection. The prognosis of ...

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

The presence of bacteria as structured biofilms in chronic wounds, especially in diabetic patients, is thought to prevent wound healing and resolution. Chronic mouse wounds models have been used to understand the underlying interactions between the microorganisms and the host. The models developed to date rely on the use of haired animals and terminal collection of wound tissue for determination of viable bacteria. While significant insight has been gained with these models, this experimental procedure requires a large number of animals and sampling is time consuming. We have developed a novel murine model that incorporates several optimal innovations to evaluate biofilm progression in chronic wounds: a) it utilizes hairless mice, eliminating the need for hair removal; b) applies pre-formed biofilms to the wounds allowing for the immediate evaluation of persistence and effect of these communities on host; c) monitors biofilm progression by quantifying light production by a genetically engineered bioluminescent strain of Pseudomonas aeruginosa, allowing real-time monitoring of the infection thus reducing the number of animals required per study. In this model, a single full-depth wound is produced on the back of STZ-induced diabetic hairless mice and inoculated with biofilms of the P. aeruginosa bioluminescent strain Xen 41. Light output from the wounds is recorded daily in an in vivo imaging system, allowing for in vivo and in situ rapid biofilm visualization and localization of biofilm bacteria within the wounds. This novel method is flexible as it can be used to study other microorganisms, including genetically engineered species and multi-species biofilms, and may be of special value in testing anti-biofilm strategies including antimicrobial occlusive dressings.

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

Here we describe a novel diabetic murine model utilizing hairless mice for real-time, non-invasive, monitoring of biofilm wound infections of bioluminescent Pseudomonas aeruginosa. This method can be adapted to evaluate infection of other bacterial species and genetically modified microorganisms, including multi-species biofilms, and test the efficacy of antibiofilm strategies.

The presence of bacteria as structured biofilms in chronic wounds, especially in diabetic patients, is thought to prevent wound healing and resolution. ...

Deep Dermal Injection As a Model of Candida albicans Skin Infection for Histological Analyses

The skin is an extremely extended organ of the body and, due to this large surface, it is continuously exposed to microorganisms. Skin damage can easily lead to infections in the dermis which can, in turn, result in the dissemination of pathogens into the bloodstream. Understanding how the immune system fights infections at the very early stage and how the host can eliminate the pathogens is an important step to set the base for future therapeutic interventions. Here we describe a model of Candida albicans infection that can visualize the processes that occur early during an infection, including when the pathogen has passed the epithelial barrier, as well as the immune response elicited by the C. albicans invasion. We used this infection model to perform histological analyses that show the immune cells that infiltrate the skin as well as the presence and localization of the pathogen. Samples collected after the infection can be processed for RNA extraction.

Deep Dermal Injection As a Model of Candida albicans Skin Infection for Histological Analyses

Here we describe a protocol that allows histological and molecular analysis of skin samples after Candida albicans intradermal injection. This protocol maintains the structural integrity of the skin and allows for the localization of tissue-resident or newly recruited immune cells as well as the pathogen distribution.

The skin is an extremely extended organ of the body and, due to this large surface, it is continuously exposed to microorganisms. Skin damage can easily ...

Protocol to Create Chronic Wounds in Diabetic Mice

Chronic wounds develop as a result of defective regulation in one or more complex cellular and molecular processes involved in proper healing. They impact ~6.5M people and cost ~$40B/year in the US alone. Although a significant effort has been invested in understanding how chronic wounds develop in humans, fundamental questions remain unanswered. Recently, we developed a novel mouse model for diabetic chronic wounds that have many characteristics of human chronic wounds. Using db/db-/- mice, we can generate chronic wounds by inducing high levels of oxidative stress (OS) in the wound tissue immediately after wounding, using a one-time treatment with inhibitors specific to the antioxidant enzymes catalase and glutathione peroxidase. These wounds have high levels of OS, develop biofilm naturally, become fully chronic within 20 days after treatment and can remain open more for more than 60 days. This novel model has many features of diabetic chronic wounds in humans and therefore can contribute significantly to advancing fundamental understanding of how wounds become chronic. This is a major breakthrough because chronic wounds in humans cause significant pain and distress to patients and result in amputation if unresolved. Moreover, these wounds are very expensive and time-consuming to treat, and lead to significant loss of personal income to patients. Advancements in this field of study through the use of our chronic wound model can significantly improve health care for millions who suffer under this debilitating condition. In this protocol, we describe in great detail the procedure to cause acute wounds to become chronic, which has not been done before.

Chronic wounds are developed from acute wounds on a diabetic mouse model by inducing high levels of oxidative stress after a full-thickness cutaneous wound. The wound is treated with inhibitors for catalase and glutathione peroxidase, resulting in impaired healing and biofilm development by bacteria present in the skin microbiome.

Chronic wounds develop as a result of defective regulation in one or more complex cellular and molecular processes involved in proper healing. They impact ...

Medicine

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Pseudomonas aeruginosa (Pa) is one of the most common opportunistic pathogens associated with cystic fibrosis (CF). Once Pa colonization is established, a large proportion of the infecting bacteria form biofilms within airway sputum. Pa biofilms isolated from CF sputum have been shown to grow in small, dense aggregates of ~10-1,000 cells that are spatially organized and exhibit clinically relevant phenotypes such as antimicrobial tolerance. One of the biggest challenges to studying how Pa aggregates respond to the changing sputum environment is the lack of nutritionally relevant and robust systems that promote aggregate formation. Using a synthetic CF sputum medium (SCFM2), the life history of Pa aggregates can be observed using confocal laser scanning microscopy (CLSM) and image analysis at the resolution of a single cell. This in vitro system allows the observation of thousands of aggregates of varying size in real time, three dimensions, and at the micron scale. At the individual and population levels, having the ability to group aggregates by phenotype and position facilitates the observation of aggregates at different developmental stages and their response to changes in the microenvironment, such as antibiotic treatment, to be differentiated with precision.

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Synthetic cystic fibrosis sputum medium (SCFM2) can be utilized in combination with both confocal laser scanning microscopy and fluorescence-activated cell sorting to observe bacterial aggregates at high resolution. This paper details methods to assess aggregate populations during antimicrobial treatment as a platform for future studies.

Pseudomonas aeruginosa (Pa) is one of the most common opportunistic pathogens associated with cystic fibrosis (CF). Once Pa colonization is established, a ...

Developing a Long-Term Swine Model for Biofilm-Infected Burn Wound Studies

Swine Model of Biofilm Infection and Invisible Wounds

Biofilm infection is a major contributor to wound chronicity. The establishment of clinically relevant experimental wound biofilm infection requires the involvement of the host immune system. Iterative changes in the host and pathogen during the formation of such clinically relevant biofilm can only occur in vivo. The swine wound model is recognized for its advantages as a powerful pre-clinical model. There are several reported approaches for studying wound biofilms. In vitro and ex vivo systems are deficient in terms of the host immune response. Short-term in vivo studies involve acute responses and, thus, do not allow for biofilm maturation, as is known to occur clinically. The first long-term swine wound biofilm study was reported in 2014. The study recognized that biofilm-infected wounds may close as determined by planimetry, but the skin barrier function of the affected site may fail to be restored. Later, this observation was validated clinically. The concept of functional wound closure was thus born. Wounds closed but deficient in skin barrier function may be viewed as invisible wounds. In this work, we seek to report the methodological details necessary to reproduce the long-term swine model of biofilm-infected severe burn injury, which is clinically relevant and has translational value. This protocol provides detailed guidance on establishing an 8 week wound biofilm infection using P. aeruginosa (PA01). Eight full-thickness burn wounds were created symmetrically on the dorsum of domestic white pigs, which were inoculated with (PA01) at day 3 post-burn; subsequently, noninvasive assessments of the wound healing were conducted at different time points using laser speckle imaging (LSI), high-resolution ultrasound (HUSD), and transepidermal water loss (TEWL). The inoculated burn wounds were covered with a four-layer dressing. Biofilms, as established and confirmed structurally by SEM at day 7 post-inoculation, compromised the functional wound closure. Such an adverse outcome is subject to reversal in response to appropriate interventions.

Author Spotlight: Studying Host-Microbe Interactions in Wound Biofilm Formation 

Chronic wounds that are resistant to antibiotics are a major threat to the healthcare system. Biofilm infections are stubborn and hostile and can cause deficient functional wound closure. We report a clinically relevant swine model of biofilm-infected full-thickness chronic wounds. This model is powerful for mechanistic studies as well as for testing interventions.

Biofilm infection is a major contributor to wound chronicity. The establishment of clinically relevant experimental wound biofilm infection requires the ...

Establishing a Mouse Model for Candida albicans Biofilm-Related PJI

A Periprosthetic Joint Candida albicans Infection Model in Mouse

Periprosthetic joint infection (PJI) is one of the common infections caused by Candida albicans (C. albicans), which increasingly concerns surgeons and scientists. Generally, biofilms that can shield C. albicans from antibiotics and immune clearance are formed at the infection site. Surgery involving the removal of the infected implant, debridement, antimicrobial treatment, and reimplantation is the gold standard for the treatment of PJI. Thus, establishing animal PJI models is of great significance for the research and development of new drugs or therapeutics for PJI. In this study, a smooth nickel-titanium alloy wire, a widely used implant in orthopedic clinics, was inserted into the femoral joint of a C57BL/6 mouse before the C. albicans were inoculated into the articular cavity along the wire. After 14 days, mature and thick biofilms were observed on the surface of implants under a scanning electronic microscope (SEM). A significantly reduced bone trabecula was found in the H&amp;E staining of the infected joint specimens. To sum up, a mouse PJI model with the advantages of easy operation, high successful rate, high repeatability, and high clinical correlation was established. This is expected to be an important model for clinical studies of C. albicans biofilm-related PJI prevention.

Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections 

Periprosthetic joint infection (PJI) caused by dangerous pathogens is common in clinical orthopedics. Existing animal models cannot accurately simulate the actual situation of PJI. Here, we established a Candida albicans biofilm-associated PJI mouse model to research and develop new therapeutics for PJI.

Periprosthetic joint infection (PJI) is one of the common infections caused by Candida albicans (C. albicans), which increasingly concerns surgeons and ...

A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection

Summary

Explore More Videos

Co-culture Models of Pseudomonas aeruginosa Biofilms Grown on Live Human Airway Cells

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Pseudomonas aeruginosa Induced Lung Injury Model

Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways

Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model

Deep Dermal Injection As a Model of Candida albicans Skin Infection for Histological Analyses

Protocol to Create Chronic Wounds in Diabetic Mice

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Swine Model of Biofilm Infection and Invisible Wounds

A Periprosthetic Joint Candida albicans Infection Model in Mouse